Resultados de Búsqueda

NICE

National Institute for Health and Clinical Excellence (NICE)

Interferon beta‑1b (Extavia) is recommended as an option for treating multiple sclerosis, only if: the person has relapsing–remitting multiple sclerosis and has had 2 or more relapses within the last 2 years or the person has secondary progressive multiple sclerosis with continuing relapses and the company provides it according to the commercial arrangement. Glatiramer acetate is recommended as an option for treating multiple sclerosis, only if: the person has relapsing–remitting ...

NICE

National Institute for Health and Clinical Excellence (NICE)

This recommendation is not intended to affect treatment with ocrelizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Current NHS treatments for relapsing–remitting multiple sclerosis include alemtuzumab, beta interferons, cladribine, dimethyl ...

NICE

National Institute for Health and Care Excellence (NICE)

Evidence on the safety and efficacy of this procedure is limited in quantity and quality. Clinicians wishing to do microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma should: - Inform the clinical governance leads in their NHS trusts. - Ensure that patients understand the uncertainty about the procedure's safety and efficacy and provide them with clear information to support shared decision-making. In addition, the use of NICE's ...

Iniciativa MAPAC (Mejorar la Adecuación de la Práctica Asistencial y Clínica)

National Institute for Health and Clinical Excellence (NICE)

These recommendations are aimed at the following population groups: educators, health professionals and pharmacists, social workers and caregivers of the elderly or people with risk factors.

NICE

National Institute for Health and Clinical Excellence (NICE)

Randomised controlled evidence did not support using ultrasound for routine monitoring of RA. However, in the committee's experience ultrasound can be useful for monitoring when clinical examination is inconclusive or is inconsistent with other signs of disease activity (for example, pain or markers of inflammation). The committee decided to make a research recommendation to inform future guidance about using ultrasound in these situations.